首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized Double-Blind Placebo-Controlled Trial
【2h】

Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized Double-Blind Placebo-Controlled Trial

机译:紫锥花预防普通感冒发作的安全性和有效性概况:一项随机双盲安慰剂对照的试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. To investigate the safety (risk) and efficacy (benefit) of Echinacea purpurea extract in the prevention of common cold episodes in a large population over a 4-month period. Methods. 755 healthy subjects were allocated to receive either an alcohol extract from freshly harvested E. purpurea (95% herba and 5% root) or placebo. Participants were required to record adverse events and to rate cold-related issues in a diary throughout the investigation period. Nasal secretions were sampled at acute colds and screened for viruses. Results. A total of 293 adverse events occurred with Echinacea and 306 with placebo treatment. Nine and 10% of participants experienced adverse events, which were at least possibly related to the study drug (adverse drug reactions). Thus, the safety of Echinacea was noninferior to placebo. Echinacea reduced the total number of cold episodes, cumulated episode days within the group, and pain-killer medicated episodes. Echinacea inhibited virally confirmed colds and especially prevented enveloped virus infections (P < 0.05). Echinacea showed maximal effects on recurrent infections, and preventive effects increased with therapy compliance and adherence to the protocol. Conclusions. Compliant prophylactic intake of E. purpurea over a 4-month period appeared to provide a positive risk to benefit ratio.
机译:目的。研究紫锥菊提取物在4个月内预防大量人群普通感冒发作的安全性(风险)和功效(效益)。方法。 755名健康受试者被分配接受新鲜收获的紫癜大肠杆菌(95%的草和5%的根)的乙醇提取物或安慰剂。在整个调查期间,参与者必须在日记中记录不良事件并评估与感冒相关的问题。在急性感冒时对鼻分泌物进行采样,并筛选病毒。结果。紫锥花共发生293次不良事件,安慰剂治疗共发生306次不良事件。 9名和10%的参与者经历了不良事件,这些不良事件至少可能与研究药物有关(药物不良反应)。因此,紫锥菊的安全性不逊于安慰剂。紫锥菊减少了感冒发作,组内累积发作天数和止痛药治疗发作的总数。紫锥菊抑制病毒确诊的感冒,特别是预防包膜病毒感染(P <0.05)。紫锥菊显示出对反复感染的最大作用,并且预防作用随治疗依从性和对方案的依从性而增加。结论。在四个月的时间里预防性摄入紫癜大肠杆菌似乎提供了正风险效益比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号